Adrenergic uptake inhibitor: Difference between revisions
imported>Robert Badgett (New page: {{subpages}} In medicine and pharmacology, '''adrenergic uptake inhibitors''' are medications that "block the transport of adrenergic transmitters into axon terminals or into s...) |
mNo edit summary |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[medicine]] and [[pharmacology]], '''adrenergic uptake inhibitors''' are [[medication]]s that "block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The [[tricyclic antidepressant]]s and [[amphetamine]]s are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of [[serotonin]]."<ref>{{MeSH}}</ref> | In [[medicine]] and [[pharmacology]], '''adrenergic uptake inhibitors''' are [[medication]]s that "block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The [[tricyclic antidepressant]]s and [[amphetamine]]s are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of [[serotonin]]."<ref>{{MeSH}}</ref> | ||
==Medical uses== | |||
===Depression=== | |||
[[Depression]] may be due to the monoamine-deficiency hypothesis, which is a "deficiency in [[serotonin]] or [[norepinephrine]] neurotransmission in the brain."<ref name="pmid18172175">{{cite journal |author=Belmaker RH, Agam G |title=Major depressive disorder |journal=N. Engl. J. Med. |volume=358 |issue=1 |pages=55–68 |year=2008 |pmid=18172175 |doi=10.1056/NEJMra073096|url=http://content.nejm.org/cgi/content/full/358/1/55}}</ref> | |||
By blocking the ''reuptake'' of [[norepinephrine]] and [[serotonin]], adrenergic update inhibitors may overcome the mono-amine deficiency.<ref name="isbn0-07-145153-6">{{cite book |author=Katzung, Bertram G. |authorlink= |editor= |others= |title=Basic and Clinical Pharmacology |edition=10th |chapter=Antidepressant Agents |chapterurl= |language= |publisher=McGraw-Hill Medical Publishing Division |location=New York |year=2006 |origyear= |pages= |quote= |isbn=0-07-145153-6 |oclc= |doi= |url=http://www.accessmedicine.com/resourceTOC.aspx?resourceID=16 |accessdate=}}</ref> | |||
===Attention deficit hyperactivity disorder=== | |||
[[Attention deficit hyperactivity disorder]] may be treated by the selective norepinephrine reuptake inhibitor, [[atomoxetine]]. | |||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 16:00, 6 July 2024
In medicine and pharmacology, adrenergic uptake inhibitors are medications that "block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin."[1]
Medical uses
Depression
Depression may be due to the monoamine-deficiency hypothesis, which is a "deficiency in serotonin or norepinephrine neurotransmission in the brain."[2]
By blocking the reuptake of norepinephrine and serotonin, adrenergic update inhibitors may overcome the mono-amine deficiency.[3]
Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder may be treated by the selective norepinephrine reuptake inhibitor, atomoxetine.
References
- ↑ Anonymous (2024), Adrenergic uptake inhibitor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Belmaker RH, Agam G (2008). "Major depressive disorder". N. Engl. J. Med. 358 (1): 55–68. DOI:10.1056/NEJMra073096. PMID 18172175. Research Blogging.
- ↑ Katzung, Bertram G. (2006). “Antidepressant Agents”, Basic and Clinical Pharmacology, 10th. New York: McGraw-Hill Medical Publishing Division. ISBN 0-07-145153-6.